Policy | August 04, 2021
India Initiates anti dumping probe against import of ATS-8 from China
Arch Pharma Labs has filed the application
Arch Pharma Labs has filed the application
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Call it a major breakthrough for diagnostic imaging
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
The protections extend through at least 2035, with the potential for further extensions
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Subscribe To Our Newsletter & Stay Updated
